Acerus to Report Second Quarter 2018 Financial Results and Host Investor Call
Aug. 03, 2018
TORONTO--(BUSINESS WIRE)--Aug 3, 2018--Acerus Pharmaceuticals Corporation (TSX:ASP) will announce its second quarter 2018 financial and operating results on Monday August 13, 2018 before market opens. The company will host a conference call on Monday, August 13 2018 at 8:30 a.m. Eastern Time.
To access the call live, please dial 416-340-2216 or 1-800-377-0758. Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays. A replay of the conference call will be available until 11:59 p.m. Eastern Time on Monday, August 20, 2018 by dialing 905-694-9451 or 1-800-408-3053, using access code: 6983647#.
Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve patient experience, with a primary focus in the field of men’s and women’s health. The Company commercializes its products via its own salesforce in Canada, and through a global network of licensed distributors in the U.S. and other territories.
Acerus currently has three marketed products: ESTRACE ®, a product for the symptomatic relief of menopausal symptoms, is commercialized in Canada; NATESTO ®, the first and only testosterone nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism, is commercialized in Canada and the U.S.; and URIVARX ®, a Natural Health Product that helps reduce symptoms of hyperactive bladder such as daytime urinary frequency, urgency and nocturia. URIVARX ® was recently approved by Health Canada and will be offered over-the-counter to Canadians dealing with such symptoms. Also, NATESTO ® has been licensed for distribution in 48 additional countries worldwide. Marketing approvals in jurisdictions outside of North America are expected to take place over the course of the coming years. In June 2018, South Korea’s Ministry of Food and Drug Safety approved NATESTO ® for the treatment of hypogonadism. Acerus’ pipeline includes six innovative products: avanafil, a new chemical entity PDE5 inhibitor for the treatment of erectile dysfunction, which has been approved by the US FDA and the EU EMA and is commercialized in the US under the trade name STENDRA ® and in the EU under the trade name SPEDRA ®; SHACT™, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; ELEGANT™ Vaginal Moisturizer, which provides comfort to women suffering from vaginal dryness, and ELEGANT™ pH, which is a pH balanced vaginal product; GYNOFLOR™, an ultra-low dose vaginal estrogen combined with a probiotic, for which a NDS has been filed in Canada for the treatment of vaginal atrophy. TEFINA™, a clinical stage product aimed at addressing a significant unmet need for women with female sexual dysfunction. Finally, Acerus is working on expanding its product portfolio by leveraging its proprietary delivery systems, patents and formulation expertise. As such, Acerus has a number of products in various stage of development. One of these projects relates to cannabinoids (whether synthetic or naturally derived cannabinoids) to be delivered intranasally to patients, which may have multiple possible therapeutic applications (the “Cannabinoids Initiative”). Acerus has filed patent applications on the Cannabinoids Initiative, is currently working on setting up a series of pharmacokinetic clinical trials and is evaluating potential commercialization pathways including partnering transactions or Acerus-led approaches.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180803005043/en/
CONTACT: Acerus Pharmaceuticals Corporation
Chief Financial Officer
KEYWORD: NORTH AMERICA CANADA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL OTHER HEALTH
SOURCE: Acerus Pharmaceuticals Corporation
Copyright Business Wire 2018.
PUB: 08/03/2018 07:00 AM/DISC: 08/03/2018 07:01 AM